Depression Research Today is a free monthly online journal that collates and summarizes the latest research about Depression, including details on clinical depression, medication, symptoms, treatment, counselling, therapy.

Remarkable effect of milnacipran, a serotonin-noradrenalin reuptake inhibitor (SNRI), on depressive symptoms in patients with Parkinson's disease who have insufficient response to selective serotonin reuptake inhibitors (SSRIs): two case reports.

Takahashi H, Kamata M, Yoshida K, Higuchi H, Shimizu T

Department of Neuropsychiatry, Akita University School of Medicine, 1-1-1, Hondo, Akita, 010-8543, Japan. hito_takahashi@hotmail.com

The authors present here two cases of Parkinson's disease with depression refractory to SSRIs treatment, who experienced a complete remission after replacing the ongoing SSRIs with a serotonin-noradrenalin reuptake inhibitor (SNRI), milnacipran. The case reports suggest that milnacipran may be one of the treatment options for depression in patients with Parkinson's disease who had inadequate response to SSRIs. Further studies are warranted to confirm this observation.

Published 7 February 2005 in Prog Neuropsychopharmacol Biol Psychiatry, 29(2): 351-3.
Full-text of this article is available online (may require subscription).

© 2004-2008 Depression Research Today. All Rights Reserved.